Acron Group’s Commercial Output Up 6% in 9M 2021
15 October 2021
Acron Group’s Commercial Output Up 6% in 9M 2021
Group’s Consolidated Output (including operating results for Acron, Dorogobuzh and North-Western Phosphorous Company)
|Product, ‘000 t||9M 2021||9M 2020||YOY, %|
|Incl. in-house consumption||2,113||1,980|
|Nitrogen fertilisers, including||3,750||3,634||3.2|
|Incl. in-house consumption||689||562|
|Incl. in-house consumption||232||170|
|Incl. in-house consumption||456||391|
|Including prilled urea||273||381||-28.5|
|Incl. in-house consumption||15||11|
|Including granulated urea||364||145||150.5|
|Incl. in-house consumption||27||19|
|Complex fertilisers, including||1,945||1,747||11.4|
|Incl. in-house consumption||40||27|
|Incl. in-house consumption||40||27|
|Total commercial output for Mineral Fertilisers||5,017||4,884||2.7|
|Organic compounds, including||367||307||19.3|
|Incl. in-house consumption||191||155|
|Incl. in-house consumption||71||57|
|Incl. in-house consumption||117||96|
|Incl. in-house consumption||4||2|
|Non-organic compounds, including:||890||757||17.5|
|Low-density and technical-grade AN||368||246||49.3|
|Liquid carbon dioxide||44||41||7.6|
|Total commercial output |
for Industrial Products
|Incl. in-house consumption||704||684|
|Total commercial output |
for Apatite Concentrate
|TOTAL COMMERCIAL OUTPUT||6,315||5,957||6.0|
Note: Commercial output is output less in-house consumption.
Comments from Alexander Popov, Chairman of Acron’s Board of Directors:
‘In 9M 2021, Acron Group set a new output record. In the reporting period, the Group produced 6,315,000 tonnes of commercial products, up 6% year-on-year. Mineral fertiliser output was up 3% to 5,017,000 tonnes.
‘The strong demand we are seeing as the global economy recovers from the COVID-19 crisis requires that we be as focused and efficient as possible. While some producers are experiencing difficulties with logistics and feedstock supply, Acron Group sees providing farmers with fertilisers as the key objective for the entire system of food production.
‘In this context, the Urea-6+ project, which significantly boosted our output of this world’s most popular fertiliser, appears to be perfectly aligned with the market’s needs. Since August, the unit has been operating at increased capacity, and the results are visible, with output of agricultural urea up 18% year-on-year. It is important for us that the project is in line with Acron’s ESG principles: the upgraded operations include a cutting-edge unit for wastewater fine treatment, which significantly reduces our environmental impact. And because we use СО2 to produce urea, the Urea-6+ project helps decrease our carbon dioxide emissions by more than 350,000 tonnes per annum.
‘Demand is strong in the industrial segment as well. The Group boosted its output of industrial products by 17% to 1,066,000 tonnes. Apatite concentrate output increased 10% to 936,000 tonnes.
‘Prices continue to head upward, but major Russian fertiliser producers froze their key fertiliser prices for domestic farmers in July 2021 through the end of the autumn agricultural season. In October, the voluntary price freeze was extended through the end of 2021’.
In Q3 2021, global urea prices continued to climb. The FOB Baltic price approached USD 600 by the end of the quarter, reaching in October a post-2008 high of USD 700. This pricing trend was fuelled by Chinese government actions limiting urea exports, an energy crisis in Europe that led several producers to suspend operations, high grain prices, recovering demand for industrial urea, and active fertiliser purchases by India and Brazil.
In early October, the FOB Baltic price of AN hit USD 450, another post-2008 record. UAN prices set a historical record of USD 600. These upward price trends were supported by higher urea prices, which serve as a benchmark for other nitrogen fertilisers.
NPK prices were on the rise as well in Q3 2021, supported by a similar pricing trend for the basic product basket (urea, DAP, and potassium chloride). The NPK 16-16-16 premium over the basic product basket was 15%.
Average Indicative Prices, USD per t, FOB Baltic/Black Sea
|Q3 2021||Q2 2021||Q3 2020||Q3 2021 /|
|Q3 2021 /|
Phone: +7 (495) 777-08-65 (ext. 5196)
Strategy and Investor Relations
Phone: +7 (495) 745-77-45 (ext. 5252)
Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics infrastructure, including three Baltic seaport terminals and distribution networks in Russia and China. Acron subsidiary North Atlantic Potash Inc. (NAP) holds mining leases and an exploration permit for ten parcels of the potassium salt deposit at Prairie Evaporite, Saskatchewan, Canada. Acron also holds a minority stake (19.8%) in Polish Grupa Azoty S.A., one of the largest chemical producers in Europe.
In 2020, the Group sold 7.8 million tonnes of its main products to 74 countries, with Russia, Brazil, Europe, and the United States as key markets.
In 2020, the Group posted consolidated IFRS revenue of RUB 119,864 million (USD 1,661 million), with EBITDA of RUB 35,311 million (USD 489 million). Acron’s shares are traded on the Moscow Exchange, and its global depositary receipts are traded at the London Stock Exchange (ticker AKRN). Acron employs over 11,000 people.
For more information about Acron Group, please visit www.acron.ru/en.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference1.12.2021 16:37:31 CET | Press release
MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at H.C. Wainwright’s 2nd Annual Psychedelics Conference on Monday, December 6th, 2021. In addition, Dr. Eriksson will participate in the ‘Future of Mental Healthcare’ panel at 2:30 p.m. Eastern Time. To attend, please register here. HMNC Brain Health’s virtual presentation will be available beginning Monday, December 6th at 7:00 a.m. Eastern Time and is accessible through the following webcast link: https://journey.ct.events/view/d77f2d7d-bff2-4d9a-8e89-620a24d1f35a. A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webca
4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab1.12.2021 15:03:00 CET | Press release
AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilities Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure. Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab. AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialization, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody. “We look forward to partnering with 4TEEN4
Kalmar’s proven straddle carrier technology to enhance operational capabilities at Kingston Freeport Terminal, Jamaica1.12.2021 15:00:00 CET | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 1 DECEMBER 2021 AT 4 PM (EET) Kalmar, part of Cargotec, has signed a contract to supply the Kingston Freeport Terminal Limited (KFTL) with four diesel-electric straddle carriers for use at their terminal in Kingston, Jamaica. The order was booked in Cargotec's 2021 Q4 order intake with delivery scheduled to be completed during Q3 2022. KFTL is a strategic transhipment hub in the Caribbean, located at the exit of the Panama Canal and the crossroads of the North/South and East/West lines. The terminal was established in 2015, and it is part of Terminal Link, a joint venture between The CMA CGM Group, a world leader in shipping and logistics, and China Merchants Port (CMP). The four Kalmar Straddle Carriers are part of a progressive fleet renewal strategy geared to improve performance and reliability in the terminal's operation. KFTL’s equipment fleet already includes Kalmar straddle carriers, reachstackers, empty container handlers and terminal tracto
Sinch carries out second part of the directed new share issue of approximately 40 million shares announced on 30 September 20211.12.2021 14:50:00 CET | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Stockholm, Sweden – December 1, 2021 - Sinch AB (publ) (“Sinch” or the “Company”) carries out a directed new share issue through the issuance of 21 million new shares for a total consideration of approximately SEK 3,469 million. The new share issue constitutes the second part of the SEK 6.6 billion new share issue of in total 40,077,841 shares (the “Shares”) announced on 30 September 2021, the proceeds of which are used to partially fund the acquisition of Pathwire. The subscribers consisted of institutional investors, among others the Canada Pension Plan Investment Board (“CPP Investments”), Temasek, SeaTown Master Fund (“SeaTown”), and SB Northstar LP,
Sinch genomför den andra delen av den riktade nyemissionen om cirka 40 miljoner aktier som offentliggjordes den 30 september 20211.12.2021 14:50:00 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Stockholm, Sverige – 1 december 2021 – Sinch AB (publ) (“Sinch” eller “Bolaget”) genomför en riktad nyemission av 21 miljoner aktier mot en total teckningslikvid om cirka 3,469 miljarder kronor. Nyemissionen utgör den andra delen av den riktade nyemissionen om totalt cirka 6,6 miljarder kronor av 40 077 841 aktier (”Aktierna”) som offentliggjordes den 30 september 2021. Emissionslikviden från den riktade nyemissionen används för att delfinansiera förvärvet av Pathwire. Tecknarna bestod av institutionella investerare, däribland Canada Pension Plan Investment Board (”CPP Investments”), Temasek, SeaTown Master Fund (”Seatown
Voyager Closes Series A Funding, Marking $10M Raised1.12.2021 14:00:00 CET | Press release
Investment to fuel growth across the marine supply chain HOUSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Voyager Portal, a software platform enabling companies to reduce cost, risk, and complexity in their marine supply chain, has today announced an $8.4 million Series A investment, led by Phaze Ventures. Other new investors include ScOp Venture Capital, Waybury Capital and Flexport. All existing investors followed in on this round. The new funding comes on the back of unprecedented growth since the company raised $1.5 million in seed money two years ago. Since then, revenue has increased 13x from Q3 2020 to Q3 2021 and was up 40% from Q2 2021. Additionally, Voyager surpassed the $1 billion-mark for freight managed on the platform. Voyager's customers include manufacturers, traders and shippers in the renewable energy, commodity trading, mining and petrochemicals industries. “Voyager Portal was created to significantly reduce cost, risk, and complexity when transporting bulk materials aroun
Agreements entered into regarding the sale of three Volvo facilities in Norway1.12.2021 13:40:00 CET | Press release
Bilia has today, as part of the agreement with Volvo Cars dated 1 October 2021, entered into agreements to sell three facilities in Norway, in the Oslo area, to the newly established company Volvo Car Stor-Oslo AS. The three facilities are located in Økern, Fornebu and Lillestrøm and conduct sales of new cars, used cars and service for Volvo cars. The sale is expected to take place on 1 July 2022. The transfer is subject to approval by the Norwegian competition authority. Gothenburg, December 1, 2021 Bilia AB (publ) For information please contact: Per Avander, Managing Director and CEO, +46 (0)10 497 70 00, firstname.lastname@example.org Kristina Franzén, CFO, +46 (0)10 497 73 40, email@example.com Facts about the Bilia Group Bilia is one of Europe’s largest car dealers with a leading position within service and sales of cars, transport vehicles and trucks. Bilia has about 160 facilities in Sweden, Norway, Germany, Luxembourg and Belgium. Bilia sells cars of the brand Volvo, BMW, Toyota,